Mr. David Pidduck reports
MEDIPHARM LABS BEGINS PRODUCTION OF FIRST ORDER FOR INTERNATIONAL EXPANSION OF NOVEL CANNABIS METERED DOSE PORTFOLIO IN THE EU AND UNITED KINGDOM UNDER BLACKPOINT SALES AND DISTRIBUTION AGREEMENT
Medipharm Labs Corp. has begun production on novel cannabis metered dose inhalers for the European Union and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Ltd., Medipharm's exclusive sales and distribution partner in those territories.
This discreet and innovative product provides patients with a smoke-free option when seeking fast onset of effects without combustion or heating. The cannabis metered dose inhaler, manufactured by Medipharm Labs under good manufacturing practices (GMP), delivers a precise dose of cannabis active pharmaceutical ingredients (API) with GMP-qualified components and excipients.
Medipharm Labs has launched metered dose inhalers in the Canadian adult-use, wellness and medical channels and expects to launch in Australia, the EU and the United Kingdom in the third quarter of this year.
Management commentary
David Pidduck, chief executive officer of Medipharm Labs, commented: "We're excited to expand our international portfolio and partner with Blackpoint to bring our innovative cannabis metered dose inhaler to the EU and United Kingdom. This smoke- and vapor-free format supports our mission to advance global access to pharma-grade cannabinoid wellness products. Successfully launching in these markets reflects the strength of our global execution strategy and our ability to manage the complexities of international compliance, logistics and market access."
David Martinez, chief executive officer of Blackpoint, added, "Working together with the highly capable team at Medipharm is exciting, and we look forward to introducing our novel and much-needed metered dose products for the benefit of the growing number of patients across the EU and United Kingdom."
Additional highlights:
-
European Union and United Kingdom exclusive supply and distribution -- Medipharm Labs is the exclusive supplier and manufacturer of the cannabis metered dose inhaler to Blackpoint and will leverage its relationships and distribution in the EU and the United Kingdom. Prohibition Partners estimated the European medicinal cannabis market to be worth 834 million euros in 2024. The agreement with Blackpoint includes minimum purchase obligations to ensure a steady supply of the product in the designated markets.
-
Innovative delivery method -- The metered dose inhaler offers a precise and repeatable dose of cannabis API, ensuring consistent and reliable patient outcomes without the stigma, smell, or byproducts of smoking or vaping.
-
GMP manufacturing -- The product is manufactured under stringent GMP standards, ensuring the highest quality and safety for medical use. Medipharm's multiple GMP certifications and global reach will enable the company to launch the product internationally.
-
Medical applications -- The inhaler is designed for medical applications, providing a discreet, familiar and effective delivery method for patients, similar to the metered dose inhaler format used in asthma treatments.
About Medipharm Labs Corp.
Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products utilizing a GMP-certified facility with ISO-standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for the delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, Medipharm Labs received a pharmaceutical drug establishment licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic good manufacturing practices licence for the extraction of multiple natural cannabinoids. This GMP licence was the first step in the company's current foreign drug manufacturing site registration with the United States Food and Drug Administration.
In 2023, Medipharm acquired Vivo Cannabis Inc., which expanded Medipharm's reach to medical patients in Canada via the Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical Pty. and Beacon Medical GmbH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.
The company carries out its operations in compliance with all applicable laws in the countries in which it operates.
We seek Safe Harbor.
© 2025 Canjex Publishing Ltd. All rights reserved.